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Prevention and Diagnosis
1 Preventing type 1 diabetes
2 Preventing type 2 diabetes
3 Diabetes risk after the menopause
4 Genetic diabetes syndromes (MODY)
5 Screening and impaired glucose tolerance
6 Type A/B diabetes and insulin resistance
1 Preventing Type 1 Diabetes
Case History
Background
Preventing or curing type 1 diabetes is one of the holy grails for those who research
autoimmune disease or treat patients with diabetes. The disease typically presents in
childhood, currently necessitates lifelong use of insulin injections and exposes the indi-
The parent of a 4-year-old boy with type 1 diabetes consults you wanting to know if there
is anything he can do to prevent a future child developing the condition. He already has an
8-year-old daughter with diabetes and there is a strong family history of autoimmune
thyroid disease on both his and his wife’s side of the family. They are contemplating
having a third child.
Is there any evidence that type 1 diabetes is preventable?
Is there any general advice the parents can usefully follow?
Can we predict the onset of type 1 diabetes?
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vidual to increased risk of vascular complications. The risk of type 1 diabetes in the gen-
eral population is about 1 in 300, and this is increased up to 20-fold in first-degree rela-
tives. Genetic markers do not provide an accurate prediction of diabetes, with only 5% of
those with susceptibility markers actually developing the disease. However, the fact that
the disease has a long latent period and that the pre-diabetic phase can be identified by
measuring islet cell antibodies or by assessing beta cell function yields an opportunity for
preventative therapy. The results of trials using non-specific immunosuppression in the
1980s were disappointing with only temporary improvements in insulin production
demonstrated.
Type 1 diabetes in children became much more common in the course of the 20th
century.1 In fact, available evidence suggests that the disease was quite uncommon,
although generally fatal, in children during the 19th century. This, along with the geo-
graphical variation in the prevalence of childhood diabetes that is not accounted for by
variations in the prevalence of susceptible genotypes, strongly suggests that environmen-
tal factors are important.2 The wide variation in incidence rates applies much more to
childhood than to adult type 1 diabetes.3 It is not surprising that there has been intensive
research into environmental triggers for diabetes that might be modified, or into safe and
effective nutritional or immunological manipulations that might decrease risk of devel-
oping the disease (Figure 1.1). Recent evidence suggests that most parents of children at
risk of type 1 diabetes will attempt preventative measures,4 and it is increasingly impor-
tant for health professionals to be able to enter into a balanced discussion with parents
and would-be parents.
Both macronutrient and micronutrient components of the diet have received atten-
tion.5 A protective effect of breast-feeding has been proposed, but not confirmed in all
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Factors Predisposing To Type 1 Diabetes Level of Evidence
Genetic (including HLA) ***
Non-breast-fed *
Early exposure to cows’ milk *
Low vitamin D status **
Viral infection *
Rapid weight gain in childhood *
The Following Do Not Appear To Modify Risk
Childhood vaccination
Treatment with nicotinamide
Oral insulin therapy
*** Strong evidence supported by multiple well-conducted and randomized clinical studies
** Reasonable evidence supported by clinical studies (not randomized)
* Some evidence supported by observational studies and expert opinion
Fig.1.1 Factors predisposing to type 1 diabetes. HLA = human leucocyte antigen.
studies. Breast-feeding may afford protection through early oral exposure to human milk
(inducing tolerance to insulin; see below), through protection against infectious agents,
and by decreasing the risk of excessive weight gain in infancy. The latter is also probably a
trigger for diabetes during adolescence. On the other hand, early exposure to cows’ milk
may increase risk through exposure to bovine insulin or -casein, the latter being a
known immunomodulatory protein contained in cows’ milk. Bottle-feeding can also be
associated with excessive weight gain. Amongst micronutrient components of the diet,
nitroso compounds (related to streptozotocin), nitrates and nitrites, all used as preserva-
tives in meat products, have been considered. Variations in vitamin D status may be
another reason for the geographical variation in the incidence of type 1 diabetes. Vitamin
D has important regulatory effects on the immune system. A protective effect of cod liver
oil (a source of both vitamin D and long-chain n-3 fatty acids, which are also anti-inflam-
matory) was shown against childhood diabetes in the recent study reported by the
Norwegian Childhood Diabetes Study Group.6
Certain infectious agents, including enteroviruses, have been associated with develop-
ment of diabetes in animal models and in rare cases of human diabetes. This has led to
worries that childhood vaccination, particularly with live attenuated vaccines, may be a
risk factor for type 1 diabetes. A Danish study, along with other recent evidence, has gone
a long way to dispel worries on this score; Hviid and colleagues7 studied a cohort includ-
ing all Danish children born between 1990 and 2000, and found no evidence of any asso-
ciation between childhood vaccinations and diabetes. On the contrary, the vaccines may
be protective by limiting the effect of potentially diabetogenic infections, particularly
rubella.
Recent Developments
1 Vitamin B3 (niacin) consists of nicotinic acid and nicotinamide. The latter is tolerated
in high doses, and has been shown to decrease the incidence of diabetes in streptozo-
tocin-treated animals, and in non-obese diabetic mice. Some early preclinical studies
showed promise for the agent. The vitamin inhibits poly-ADP-ribose polymerase
(PARP), an enzyme involved in DNA repair. Activation of PARP leads to depletion of
intracellular nicotinamide adenine dinucleotide. This depletion of cellular energy
stores may predispose to cell damage, including in the pancreatic beta cell. The
European Nicotinamide Diabetes Intervention Trial (ENDIT)8 was a randomized,
double-blind, placebo-controlled trial in which 552 islet cell antibody-positive first-
degree relatives of patients with diabetes took either nicotinamide or placebo. There
was no difference in the incidence of diabetes during the five years of the trial (82 vs 77
cases, respectively).
2 Autoimmunity directed at insulin epitopes is one of the critical driving forces in the
pathogenesis of type 1 diabetes. In animal models, exposure to mucosal insulin
induces tolerance and thus decreases risk of diabetes. This mechanism is of particular
interest because of the recent developments of insulin formulations which are active
after oral or nasal administration. The Diabetes Prevention Trial-Type 1 reported
recently.9 In this trial, a large number of first- and second-degree relatives of patients
with diabetes were screened for pre-diabetes. Those found to be positive were ran-
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domized to receive either oral insulin or placebo. Again, there was no difference in the
incidence of new diabetes between the control and the treatment groups.
3 The prospects of gene therapy for diabetes are improving rapidly. Approaches to
introduce a functioning insulin-producing mechanism in glucose-responsive cells
have been considered. The genetic susceptibility to diabetes is mainly through class II
histocompatibility alleles. Recent experiments in non-obese diabetic mice have been
carried out to replace diabetes-prone genes with those that are protective.10
Conclusion
There is not, currently, any way to accurately predict which individuals are going to get
diabetes, or to prevent its occurrence. Family history is a major risk factor, increasing sus-
ceptibility by up to 20-fold, and there might be a slight bias towards males developing dia-
betes. Epidemiological data strongly support a role for environmental influences,
especially for childhood diabetes. There is no evidence currently to support specific pre-
ventative measures. Breast-feeding should be promoted for its possible role in preventing
type 1 diabetes, as well as its other health benefits. Efforts to limit excessive weight gain in
infancy and adolescence should be promoted, as high body weight at these times may
favour development of type 1 diabetes. Among the other nutritional factors, the best evi-
dence is for a protective effect of vitamin D and supplementation should be considered
(perhaps as cod liver oil) in areas where sunlight exposure is low. Finally, parents should
be encouraged to have their children vaccinated as per normal childhood schedules—
there is no evidence that vaccination predisposes to diabetes and it may be that, by
decreasing infection with some agents, it actually protects.
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2 Preventing Type 2 Diabetes
Case History
Background
Once the condition is established, it is extremely difficult to maintain tight control of
blood glucose and other vascular risk factors in patients with type 2 diabetes. A number
of very important studies have been published in the past three years demonstrating the
potential for lifestyle interventions and drugs to either prevent diabetes, or at least to
delay its onset. These studies, along with the acknowledged costs of managing patients
with type 2 diabetes, have heightened awareness of the value of preventative measures.
The best-known of the prevention studies is the Diabetes Prevention Program (DPP),
carried out in 27 North American centres.1 In this study, 3234 non-diabetic patients with
impaired glucose tolerance were randomly assigned to placebo, metformin (850 mg twice
daily) or lifestyle intervention. The latter consisted of dietary advice plus at least 150 min-
You are consulted by a 43-year-old man who has a strong family history of diabetes. He is
concerned because his father developed diabetes at the age of 56 and has recently (aged
60 years) had a lower limb amputation. Your patient is generally in good health. He has a
body mass index of 28 kg/m2 and takes very little exercise as he has a busy job and a young
family. He smokes 20 cigarettes per day, and has been noted to be mildly hypertensive
although not requiring treatment at present. 
How would you advise him?
Are we able to prevent development of type 2 diabetes?
Is there a role for drug therapy?
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utes of physical activity per week. After 2.8 years of follow-up, the incidence of diabetes
was 11.0, 7.8 and 4.8 cases per 100 patient-years in the placebo, metformin and lifestyle
groups, respectively. Metformin reduced the incidence of new diabetes by 31%, while
lifestyle intervention reduced it by 58%. Some of the benefit associated with metformin
use is lost after the drug is stopped. However, a recent washout study using the DPP
cohort confirms that much of the benefit persists.2 A very recent cost–benefit analysis of
this study confirmed that both interventions were cost effective.3 However, lifestyle inter-
vention was much more cost effective with a cost, relative to placebo, of $1100 per quali-
ty-adjusted life-year, compared with $31 300 for metformin.
The benefit of lifestyle intervention was confirmed in the Finnish Diabetes Prevention
Study (DPS).4 Usual diabetes care was compared with a lifestyle intervention programme
in 522 overweight, middle-aged subjects with impaired glucose tolerance. The lifestyle
intervention group experienced greater weight loss and improved glycaemic and lipid
parameters. The STOP-NIDDM trial5 (Study to Prevent Non-Insulin-Dependent
Diabetes Mellitus) randomized 714 patients with impaired glucose tolerance to either
placebo or acarbose, and followed them up for over three years. Forty-two per cent of
patients in the placebo wing and 32% of patients taking acarbose developed diabetes. The
decrease in new diabetes was highly significant, although the study has been criticized
because of possible bias due to the large proportion of patients that did not complete
their treatment regime. There is further evidence that drug treatment can prevent, or
delay the onset of, diabetes from small studies using either sulphonylureas or the thiazo-
lidinedione drug, troglitazone.6
One in five of the population in most developed countries is now obese, and this is the
major factor underlying the global increase in diabetes prevalence in recent years. It is not
surprising, therefore, that obesity has become an increasing focus for treatment and pre-
vention of diabetes and cardiovascular disease. In the XENDOS study (XENical in the
prevention of Diabetes in Obese Subjects), 3305 patients were treated with lifestyle inter-
vention and randomized either to placebo or to treatment with the gastrointestinal lipase
inhibitor, orlistat.7 After four years’ treatment, diabetes had developed in 9.0% of placebo
patients and in 6.2% of orlistat-treated patients. Patients treated with orlistat also lost
more weight and had improved lipid profiles. Again, and as with many long-term studies
in this area, a relatively large proportion of patients did not complete the study.
In summary, a number of recent studies confirm that both lifestyle interventions and
drug treatments can reduce the incidence of new diagnoses of diabetes, and also improve
some of the associated cardiovascular risk factors (Figure 2.1). Lifestyle intervention is
clearly preferable, particularly if changes can be sustained long-term. Diet and exercise
can also be cost-effective interventions. For those who do not succeed with lifestyle man-
agement, drug treatment appears to be both a safe and an effective option.
Recent Developments
1 Other drug groups used in the prevention of cardiovascular disease may affect the
development of diabetes.6 Blockade of the renin–angiotensin system has now been
shown in several studies, including the Heart Outcomes Protection Evaluation
(HOPE) study, to modestly decrease incidence of diabetes. Lipid-lowering drugs may
have a similar effect, perhaps by decreasing insulin resistance. For some patients, vig-
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orous treatment of cardiovascular risk factors may be the best line of attack, and
decreased risk of diabetes an important secondary benefit of treatment.
2 Individuals at high risk of vascular disease should have vigorous management of their
multiple risk factors wherever possible. One of the largest randomized trials of life-
style intervention conducted is the Multiple Risk Factor Intervention Trial (MRFIT).
Recent data8 from nearly 13 000 men followed for up to seven years show, again, that
diet and exercise can prevent diabetes. However, there were interesting differences
between smokers and non-smokers; with lifestyle intervention, diabetes incidence
was 18% lower in non-smokers but 26% higher in smokers. The exact reasons for this
are not clear but use of antihypertensive drugs in smokers and weight gain associated
with attempts to quit smoking are possible confounding factors.
3 The role of exercise in improving glucose tolerance is now well established.
Traditionally, vigorous aerobic exercise was recommended but was often unpalatable
or unachievable for overweight and untrained subjects. Now, almost any type of exer-
cise—depending on the patient’s preferences and capabilities—is regarded as benefi-
cial. Recent data from the Finnish Diabetes Prevention Study have confirmed the link
between leisure-time physical activity and reduced risk of diabetes.9 Even low-
intensity and walking activity were associated with improved glucose tolerance.
4 There is currently great focus on the effects of diets with differing macronutrient
contents. Diets that are low glycaemic index, high in fibre and rich in wholegrain
foodstuffs can improve glucose tolerance and diminish the risk of developing dia-
betes. These findings have been confirmed in a number of substantial studies pub-
lished in the past two years. In one recent study involving over 36 000 Australian
2 Preventing type 2 diabetes 7
Review Diet
Exercise Plan
Hypertensive Normotensive
Orlistat Sibutramine?Metformin
Other Risk Factors
(Smoking/Blood Pressure/Lipids/?Aspirin)
Fig. 2.1 Figure shows suggested scheme for prevention of type 2 diabetes using lifestyle interventions and
anti-obesity drugs.
men,10 consumption of a low glycaemic diet correlated strongly with a decreased risk
of diabetes. Also, and in keeping with other studies, low dietary magnesium intake
was also associated with increased risk of diabetes.
Conclusion
Given the difficulty experienced in reducing the risk associated with type 2 diabetes once
the condition has developed, it seems imperative to try to prevent the condition when-
ever the opportunity arises. Although the above patient is fit and healthy at present, he is at
risk in the future of developing type 2 diabetes. Initial management should be with dietary
advice from a registered dietician and the patient should be advised about the benefits of
exercise. Even a modest increase in low-intensity activity might be of benefit. He should
have a thorough assessment of his overall cardiovascular risk and, if necessary, receive
treatment for poorly controlled risk factors. Given that he is healthy and young, he should
be strongly advised to keep his weight down and to engage in regular physical activity.
Once he commences drug therapy, he is likely to take it for life. He should be advised to
stop smoking and offered smoking cessation support if needed. This will reduce his risk of
cardiovascular events and may also decrease his risk of diabetes. His glycaemic status
should be assessed by fasting blood glucose and, preferably, also with a random or post-
prandial measurement. Drug therapy—for example with metformin—could be con-
sidered if he has impaired glucose tolerance. The benefit is not likely to be as great as that
with diet and exercise, and this should be repeatedly emphasized to the patient.
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3 Diabetes Risk after the Menopause
Case History
Background
Compared with men, women are relatively protected from cardiovascular disease except
when they are post-menopausal or they have diabetes. Sex steroids have important roles
in regulating lipid metabolism, endothelial function, blood vessel tone and other aspects
of vascular function. Menopause is associated with a relatively abrupt decrease in circu-
lating oestrogen. There is no comparable process in men. Since the general population is
aging, and women spend an increasing proportion of their life in an oestrogen-deficient
A 54-year-old Afro-Caribbean woman is referred to you. She is two years post-
menopausal and type 2 diabetes was diagnosed eight months ago. Despite having visited
the dietician three times since then, her body mass index remains high at 30 kg/m2. She
takes atenolol 50 mg/day for hypertension, which is well controlled. Diabetes is treated by
diet alone, and her glycosylated haemoglobin (HbA1c) is reasonable at 7.1%. Fasting
cholesterol is 5.8 mmol/l and triglycerides 2.5 mmol/l.  She has a strong family history of
type 2 diabetes.
How would you manage her diabetes and hypertension?
Is her age and menopausal status relevant to her management?
Is her racial background important?
She wants to know whether she should consider hormone replacement therapy
3 Diabetes risk after the menopause 9
P R O B L E M
state in which they are at risk of atherosclerotic disorders, management of cardiovascular
risk in the peri- and post-menopausal periods is of particular importance.
The period of declining ovarian function leading up to the menopause, the peri-
menopause, is associated with declining sex steroid levels and important alterations in
body composition. Thus total and visceral adiposity increase, and bone mineral density
decreases. The change in fat mass and distribution may relate to decreased lipolysis and
increased activity of lipoprotein lipase. Weight gain around the menopause is greater in
women from more deprived socio-economic backgrounds and in those who do not
smoke, do not exercise regularly and have never used HRT. In a prospective 9-year study
of women during the menopausal transition, Guthrie et al.1 demonstrated that mood
changes and decreased quality of life appeared to contribute to the changes in body
composition and cardiovascular risk profile around the menopause.
HRT is not currently recommended for prevention of cardiovascular disease. Although
benefits in risk-markers have been documented, there is debate about which oestrogen,
which progestogen, or which combination, and which route of administration. Set against
the possibility of a marginal benefit in cardiovascular disease prevention, there is un-
doubtedly increased risk of thromboembolic events and breast cancer. Moreover, two
important trials—the Women’s Health Initiative (WHI) and the Hormone Estrogen-
Progestin Replacement Study (HERS)—actually reported increased cardiac events in the
short term. A recent large, Swedish study2 appears to confirm that oestrogen use can
improve cardiovascular risk profile and there are now several lines of evidence that either
oral or transdermal oestrogen may improve insulin sensitivity and slow the progress of the
metabolic syndrome, thus retarding development of diabetes in those at risk.3
The impact of diabetes on cardiovascular risk is higher for women than it is for men.
In a recent Finnish study,4 the event rate per 1000 patient-years was 11.6 for non-diabetic
men and 1.8 for non-diabetic women, while comparable event rates for males and
females with diabetes were 36.3 and 31.6, respectively. In the recent Study of Women’s
health Across the Nation (SWAN),5 differences between insulin sensitivity and beta cell
function were compared in groups of pre- or peri-menopausal women from differing
racial backgrounds. Insulin sensitivity was lower in African-Americans compared with
other racial groups, while beta cell function was relatively preserved in this group. Thus
measures to improve insulin sensitivity, including weight loss, should be the approach of
choice in this group.
Recent Developments
1 Increased abdominal obesity in women is linked with insulin resistance and with
markers of inflammation that predispose to ischaemic heart disease and other com-
plications of obesity (Figure 3.1).6 Although visceral obesity does not account for all
of the increased risk associated with the post-menopausal state, it is an important
therapeutic target, and regular exercise goes a long way to ameliorate the fat accumu-
lation and accompanying risk factors.7
2 Attempts to improve health and deal with cardiovascular risk factors should not wait
until the menopause. Recent data from the Nurses Health Study8 demonstrate that
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increasing obesity in the pre-menopause is associated with increased levels of inflam-
matory markers (tumour necrosis factor-receptor, interleukin-6 and C-reactive pro-
tein), and these markers are predictive of the development of diabetes.
3 Micronutrient status also changes around the time of the menopause and there is con-
siderable evidence now that some of these changes may relate to risk of diabetes and
cardiovascular disease. Thus, decreased magnesium levels are more common after
the menopause, and predispose to insulin resistance and the metabolic syndrome.9
Increased iron stores are associated with increased cardiovascular risk factors,10 and
this may be a factor in the peri-menopausal period for many women.11
Conclusion
This woman is at increased risk on the grounds of age, ethnicity, menopausal status and
the fact that she has diabetes. She should try hard with diet and exercise to manage her
weight and glycaemic control (Figure 3.2). Given her imperfect glycaemic control at pres-
ent, she might consider metformin to help preserve her beta cell function long term. Her
hypertension is well controlled but atenolol might not be the ideal agent given her weight
and imperfect glycaemic control. An angiotensin-converting enzyme inhibitor or angio-
tensin II receptor blocker might be preferable. HRT is not routinely recommended for
cardiovascular disease prevention but patient choice is important, and she may consider
this if she is experiencing menopausal symptoms. She may benefit from aspirin treatment
(see Chapter 33).
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Fig. 3.1 Contributions of visceral adipose tissue (VAT) and insulin resistance (IR) to risk of diabetes. Post-
menopausal women were screened for diabetes using an oral glucose tolerance test. Diabetes was
particularly prevalent in women who had both increased visceral adipose tissue and insulin resistance. 
*P <0.0001. Source: Piché et al. 2005.6
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Make patient aware:
Heightened vascular risk
Importance of diet and exercise
? HRT
Consider if patient has 
menopausal symptoms
Glycaemic control
Beware of weight gain
Assess cardiovascular 
risk profile
Treat blood pressure and 
lipids
Consider aspirin
Fig. 3.2 Figure suggests a scheme for managing cardiovascular risk in a patient approaching, or soon after,
the menopause. HRT = hormone replacement therapy.
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4 Genetic Diabetes Syndromes (MODY)
Case History
Background
Maturity-onset diabetes of youth (MODY) is an unusual cause of diabetes, and accounts
for 1–2% of all cases of diabetes. The fact that the diagnosis is seldom made in clinical
practice almost certainly reflects the fact that there is no simple clinical test for the syn-
drome and it is, therefore, under-diagnosed. It is important to recognize MODY for a
number of reasons: the syndrome is usually diagnosed in adolescence or early adulthood
and patients may thus have diabetes for a substantial portion of their life; there is an
appreciable risk of diabetic complications even though the degree of hyperglycaemia may
be mild; the approach to treatment is different to that to either type 1 or type 2 diabetes;
and other family members are usually affected. Diabetes usually develops before the age
A 24-year-old woman attends your clinic for annual diabetes review. She was diagnosed
with diabetes at the age of 18 years. She is not overweight. She checks her blood sugar
two days per week and fasting values are always below 7.0 mmol/l and her glycosylated
haemoglobin (HbA1c) is 5.8%. She takes gliclazide 80 mg/day. Checking her eyes, you find
that she has moderate diabetic retinopathy. Her blood pressure is 138/92 mmHg. She has
a brother who was diagnosed with diabetes at the age of 18 and commenced on insulin. 
What type of diabetes does she have?
How would you manage her?
What is her prognosis regarding diabetic complications?
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